Orexo has appointed Petter Backgren as the new chief executive officer (CEO) for its diagnostic subsidiary Kibion, replacing acting CEO Erik Bergman, effective 15 November.
Backgren has experience in sales and marketing and general management within the pharma and diagnostic sectors, both in the Nordic countries and internationally.
Backgren has been working as general manager of the Clinical Diagnostics Business at DiaSorin for the UK, Ireland and Nordic region since 2009.
He has previously worked for Novartis, where he held several positions including regional business manager and head of Sales in General Medicine.
Orexois president and CEO Torbjorn Bjerke said that Backgren’s experience and background will contribute to Kibion’s continued growth and value increase and would also like to thank Erik Bergman for his contributions to Kibion both as CFO and as acting CEO.